Please use this identifier to cite or link to this item: http://ir.mu.ac.ke:8080/jspui/handle/123456789/8056
Title: Prevention of maternal and neonatal death/infections with a single oral dose of azithromycin in women in labour in low-income and middle-income countries (A-PLUS): a study protocol for a multinational, randomised placebo- controlled clinical trial
Authors: Hemingway-Foday, Jennifer
Tita, Alan
Chomba, Elwyn
Mwenechanya, Musaku
Mweemba, Trecious
Nolen, Tracy
Lokangaka, Adrien
Kitoto, Antoinette Tshefu
Lomendje, Gustave
Hibberd, Patricia L.
Patel, Archana
Das, Prabir Kumar
Kurhe, Kunal
Goudar, Shivaprasad S.
Kavi, Avinash
Metgud, Mrityunjay
Saleem, Sarah
Tikmani, Shiyam S.
Esamai, Fabian
Nyongesa, Paul
Sagwe, Amos
Keywords: Maternal death
Neonatal death
Issue Date: 2023
Abstract: Introduction Maternal and neonatal infections are among the most frequent causes of maternal and neonatal mortality, and current antibiotic strategies have been ineffective in preventing many of these deaths. A randomised clinical trial conducted in a single site in The Gambia showed that treatment with an oral dose of 2 g azithromycin versus placebo for all women in labour reduced certain maternal and neonatal infections. However, it is unknown if this therapy reduces maternal and neonatal sepsis and mortality. In a large, multinational randomised trial, we will evaluate the impact of azithromycin given in labour to improve maternal and newborn outcomes. Methods and analysis This randomised, placebo- controlled, multicentre clinical trial includes two primary hypotheses, one maternal and one neonatal. The maternal hypothesis is to test whether a single, prophylactic intrapartum oral dose of 2 g azithromycin given to women in labour will reduce maternal death or sepsis. The neonatal hypothesis will test whether this intervention will reduce intrapartum/neonatal death or sepsis. The intervention is a single, prophylactic intrapartum oral dose of 2 g azithromycin, compared with a single intrapartum oral dose of an identical appearing placebo. A total of 34 000 labouring women from 8 research sites in sub- Saharan Africa, South Asia and Latin America will be randomised with a one-to-one ratio to intervention/ placebo. In addition, we will assess antimicrobial resistance in a sample of women and their newborns. Ethics and dissemination The study protocol has been reviewed and ethics approval obtained from all the relevant ethical review boards at each research site. The results will be disseminated via peer-reviewed journals and national and international scientific forums.
URI: http://dx.doi.org/10.1136/ bmjopen-2022- 067581
http://ir.mu.ac.ke:8080/jspui/handle/123456789/8056
Appears in Collections:School of Medicine

Files in This Item:
File Description SizeFormat 
Prevention_of_maternal_and_neonatal_deathinfection.pdf789.66 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.